Effect of Bamlanivimab (LY-CoV555) Antibody Treatment on Viral Load & Clinical Outcomes for COVID-19
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19N Engl J Med. 2020 Oct 28.
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Four hundred and fifty two patients who tested positive for coronavirus disease 19 (COVID19) were randomized to receive a single intravenous infusion of LY-CoV555, at a dose of 700mg, 2800mg, or 7000mg, or placebo, for the reduction of viral load and amelioration of symptoms. The primary outcome of interest was the change from baseline in viral load at 11 days follow up. Secondary outcomes of inte...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE